Concentrations of chemical mediators in nasal secretions after nasal allergen challenges in atopic patients.
By using a microsuction technique, a quantitative determination of chemical mediators in nasal secretions was performed in 18 hay-fever patients and in a control group of 10 healthy volunteers. The authors then compared these quantitative data for mediators with objective nasal findings counting the number of sneezes, passive anterior rhinomanometry (PAR) and nasal inspiratory peak flow. A sampling protocol was designed with a follow-up of 3 days after nasal allergen challenge (NAC) in order to investigate both early and late allergic reactions. Median baseline concentrations of five major mediators were obtained: histamine, 19 ng/g; leukotriene C4 (LTC4), 5.7 ng/g. tryptase, 0; prostaglandin D2 (PGD2), 477 pg/g; eosinophil cationic protein (ECP), 105 ng/g. Significant increases in histamine (214 ng/g), LTC4 (20 ng/g) and tryptase (28 microU/g) were found, but a significant decrease occurred in ECP (47 ng/g) and PGD (226 pg/g) immediately after NAC in the patients studied. Most ECP concentrations (94%) increased slowly 1 h after NAC and reached a significantly higher level 24 h later. In evaluating nasal symptoms, sneezes were present in a high percentage of cases (76%) during the early phase but were uncommon during the late phase (29%). Total nasal obstruction occurred in 94% during the early phase. In contrast, unilateral nasal obstruction presented in 82% during the late phase, whereas total nasal obstruction was present only in 41%. The most common type of late phase nasal obstruction shown by PAR was alternating nasal obstruction.
Wang
D
D
Department of Otorhinolaryngology, University Hospital, Free University of Brussels, Belgium.
Clement
P
P
Smitz
J
J
Derde
M P
MP
D000293:Adolescent; D000328:Adult; D000485:Allergens; D001798:Blood Proteins / Q000032:analysis; D016022:Case-Control Studies; D053818:Chymases; D047091:Eosinophil Granule Proteins; D005260:Female; D005500:Follow-Up Studies; D006632:Histamine / Q000032:analysis; D006801:Humans; D018836:Inflammation Mediators / Q000032:analysis*; D001239:Inhalation / Q000502:physiology; D017997:Leukotriene C4 / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009297:Nasal Mucosa / Q000378:metabolism*; D015508:Nasal Obstruction / Q000503:physiopathology; D009299:Nasal Provocation Tests; D015230:Prostaglandin D2 / Q000032:analysis; D006255:Rhinitis, Allergic, Seasonal / Q000378:metabolism / Q000503:physiopathology*; D012260:Ribonucleases; D012697:Serine Endopeptidases / Q000032:analysis; D012912:Sneezing / Q000502:physiology; D053802:Tryptases
D000485:Allergens; D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D018836:Inflammation Mediators; D017997:Leukotriene C4; D006632:Histamine; D012260:Ribonucleases; D012697:Serine Endopeptidases; C083294:chymase 2; D053818:Chymases; D053802:Tryptases; D015230:Prostaglandin D2